First Gaucher type 3 neurological drug approved
-
By
-
Teraya Smith
-
November 18, 2026
-
2 min
By
Teraya Smith
November 18, 2026
A deadly conviction, healing vanilla, stormy lungs, and a COVID tea party await.
by Teraya Smith
October 15, 2026
Several FDA decisions across multiple specialties are expected this month.
August 28, 2026
The antisense oligonucleotide reduces production of the abnormal protein that accumulates in supportive cells in the brain.
September 4, 2026